An evaluation of anti-TNF-alpha-therapy in patients with ankylosing spondylitis: Imbalanced activation of NF kappa B subunits in lymphocytes and modulation of serum cortisol concentration

Rheumatology International

Volumn 27, Issue 9, 2007, Pages 841-846

  Eggert, Martin ^a   Seeck, Ulrike ^a   Semmler, Marco ^a   Maaß, Ulrich ^a   Dietmann, Sabine ^c   Schulz, Martin ^b   Dotzlaw, Helmut ^b   Neeck, Gunther ^a  

^a Center of Rheumatology   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Ankylosing spondylitis; Anti TNF therapy; Glucocorticoids; Lymphocytes; NF B

Indexed keywords

C REACTIVE PROTEIN; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 6; PROTEIN P50; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; COURSE EVALUATION; DISEASE ACTIVITY; DNA BINDING; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SAMPLE SIZE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DNA-BINDING PROTEINS; FEMALE; HUMANS; HYDROCORTISONE; INTERLEUKIN-6; LYMPHOCYTES; MALE; MIDDLE AGED; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; SPONDYLITIS, ANKYLOSING; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34250196526     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0303-z     Document Type: Article

References (25)

1. Brown MA, Crane AM, Wordsworth BP (2002) Genetic aspects of susceptibility, severity, and clinical expression in ankylosing spondylitis. Curr Opin Rheumatol 14(4):354-360
2. Brandt J, Haibel H, Cornely D, Golder W, Gonzales J, Reddig J, Thriene W, Sieper J, Braun J (2001) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43(6):1346-1352
3. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(Suppl 3):iii8-iii18
4. Scalapino KJ, Davis JC Jr (2003) The treatment of ankylosing spondylitis. Clin Exp Med 2(4):159-165
5. Liu Y, Cortinovis D, Stone MA (2004) Recent advances in the treatment of the spondyloarthropathies. Curr Opin Rheumatol 16(4):357-365
6. Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA (2005) Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 64(6):940-942
7. Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18(49):6853-6866
8. Palanki MS (2002) Inhibitors of AP-1 and NF-kappa B mediated transcriptional activation: therapeutic potential in autoimmune diseases and structural diversity. Curr Med Chem 9(2):219-227
9. Eggert M, Kluter A, Zettl UK, Neeck G (2004) Transcription factors in autoimmune diseases. Curr Pharm Des 10(23):2787-2796
10. Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141-179
11. Chen FE, Ghosh G (1999) Regulation of DNA-binding by Rel/NF-kappa B transcription factors: structural views. Oncogene 18(49):6845-6852
12. Bacher S, Schmitz ML (2004) The NF-kappaB pathway as a potential target for autoimmune disease therapy. Curr Pharm Des 10(23):2827-2837
13. Heissmeyer V, Krappmann D, Wulczyn FG, Scheidereit C (1999) NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes. EMBO J 18(17):4766-4778
14. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr (1995) Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 15(2):943-953
15. Ray A, Prefontaine KE (1994) Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci 91(2):752-756
16. Neeck G, Renkawitz R, Eggert M (2002) Molecular aspects of glucocorticoid hormone action in rheumatoid arthritis. Cytokines Cell Mol Ther 7(2):61-69
17. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34(10):1218-1227
18. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286-2291
19. Eggert M, Klüter A, Rusch D, Schmidt KL, Dotzlaw H, Schulz M, Pabst W, Böke J, Renkawitz R, Neeck G (2002) Expression analysis of the glucocorticoid receptor and the nuclear factor-kB subunit p50 in lymphocytes from patients with rheumatoid arthritis. J Rheumatol 29(12):2500-2506
20. Swaak AJ, van Rooyen A, Nieuwenhuis E, Aarden LA (1988) Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol 17(6):469-474
21. McKay LI, Cidlowski JA (1998) Cross-talkbetween nuclear factor-kappa B and the steroidhormone receptors: mechanisms of mutual antagonism. Mol Endocrinol 12(1):45-56
22. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270(5234):232-233
23. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr (1995) Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270(5234):283-286
24. Voleti B, Agrawal A (2005) Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-kappaB on the proximal promoter. J Immunol. 175(5):3386-3390
25. Vincenti MP, Brinckerhoff CE (2002) Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 4(3):157-164